News

Small but versatile – Key players in the marine nitrogen cycle can utilize cyanate and urea

Valneva and HOOKIPA Sign a Collaboration and Manufacturing Agreement

AOP Orphan announces three-year results on Ropeginterferon alfa-2b in Polycythemia Vera at ASH

AWARD FOR PHAGE THERAPY: PHAGOMED WINS AUSTRIAN ENTREPRENEURSHIP AWARD PHÖNIX

EANS-Adhoc: Marinomed Biotech AG suspends offer period of the current IPO

HOOKIPA and DarwinHealth Enter into a Research Collaboration and License Agreement

VIENNESE BIOTECH COMPANY MARINOMED DEMONSTRATES THE BENEFITS OF ITS PATENTED MARINOSOLV® TECHNOLOGY

Arsanis and X4 Pharmaceuticals Agree to Merger

ERC consolidator grant for Kikuë Tachibana

Study on parasites in dog faeces comes to surprising conclusion

Brigitte Ederer joins the Supervisory Board of Marinomed

EUR 96 million of EIF and aws finance for innovative businesses in Austria

EMERGENT BIOSOLUTIONS AND VALNEVA REPORT POSITIVE PHASE 1 RESULTS FOR THEIR VACCINE CANDIDATE AGAINST THE ZIKA VIRUS

Rentschler Fill Solutions inaugurates state-of-the-art fill and finish facility

Marinomed launches Initial Public Offering on the Vienna Stock Exchange

HOOKIPA Appoints Julie O’Neill as a Non-Executive Director

Arsanis Reports Financial Results for Third Quarter 2018

Themis Bioscience Postpones its Listing on Euronext Amsterdam

Valneva Reports Nine Month Results for 2018, Confirms Guidance, Strengthens Balance Sheet with €50m Financing

Themis Bioscience Publishes Compelling Phase 2 Results for Lead Vaccine Candidate against Chikungunya Fever in the Lancet